DK3341379T3 - EZH2-hæmmere - Google Patents

EZH2-hæmmere Download PDF

Info

Publication number
DK3341379T3
DK3341379T3 DK16757513T DK16757513T DK3341379T3 DK 3341379 T3 DK3341379 T3 DK 3341379T3 DK 16757513 T DK16757513 T DK 16757513T DK 16757513 T DK16757513 T DK 16757513T DK 3341379 T3 DK3341379 T3 DK 3341379T3
Authority
DK
Denmark
Prior art keywords
ezh2 inhibitors
ezh2
inhibitors
Prior art date
Application number
DK16757513T
Other languages
English (en)
Inventor
Esteban Dominguez
Deqi Guo
Mary Margaret Mader
Anh-Quan Hannah Nguyen
Prado Miriam Filadelfa Del
Michael Enrico Richett
Michael John Rodriguez
Yvonne Yee Mai Yip
Kuo-Long Yu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3341379T3 publication Critical patent/DK3341379T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
DK16757513T 2015-08-27 2016-08-22 EZH2-hæmmere DK3341379T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382433 2015-08-27
EP15382615 2015-12-11
PCT/US2016/047989 WO2017035060A1 (en) 2015-08-27 2016-08-22 Inhibitors of ezh2

Publications (1)

Publication Number Publication Date
DK3341379T3 true DK3341379T3 (da) 2019-12-02

Family

ID=56801893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16757513T DK3341379T3 (da) 2015-08-27 2016-08-22 EZH2-hæmmere

Country Status (31)

Country Link
US (1) US9718838B2 (da)
EP (1) EP3341379B1 (da)
JP (1) JP6704040B2 (da)
KR (1) KR20180030704A (da)
CN (1) CN107922434B (da)
AU (1) AU2016313541A1 (da)
BR (1) BR112018003108A2 (da)
CA (1) CA2994428A1 (da)
CO (1) CO2018002033A2 (da)
CR (1) CR20180104A (da)
CY (1) CY1122364T1 (da)
DK (1) DK3341379T3 (da)
DO (1) DOP2018000058A (da)
EC (1) ECSP18014798A (da)
ES (1) ES2756603T3 (da)
HR (1) HRP20192101T1 (da)
HU (1) HUE047630T2 (da)
IL (1) IL257061A (da)
LT (1) LT3341379T (da)
MD (1) MD3341379T2 (da)
ME (1) ME03650B (da)
MX (1) MX2018002484A (da)
PE (1) PE20181025A1 (da)
PH (1) PH12018500423A1 (da)
PL (1) PL3341379T3 (da)
PT (1) PT3341379T (da)
RS (1) RS59615B1 (da)
SI (1) SI3341379T1 (da)
TN (1) TN2018000058A1 (da)
TW (1) TW201718598A (da)
WO (1) WO2017035060A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5483515B2 (ja) * 1999-04-22 2014-05-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
US10604531B2 (en) * 2016-05-05 2020-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3469099A1 (en) * 2016-06-08 2019-04-17 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
US20210188813A1 (en) * 2018-04-24 2021-06-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007712A2 (en) * 2000-07-24 2002-01-31 Pharmacia & Upjohn Company Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
CA2420164A1 (en) * 2000-10-20 2002-05-02 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1620449A4 (en) 2003-02-14 2008-10-01 Smithkline Beecham Corp NUCLEIC ACIDS WITH DIFFERENTIAL EXPRESSION THAT CORRELATE WITH KSP EXPRESSION
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
BR112012028556A2 (pt) 2010-05-07 2014-04-01 Glaxosmithkline Llc Indóis
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (ja) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2718900T3 (es) 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
WO2013155434A1 (en) 2012-04-12 2013-10-17 E. I. Du Pont De Nemours And Company Can tap
KR20230004871A (ko) 2012-04-13 2023-01-06 에피자임, 인코포레이티드 암 치료용 병용 요법
SG11201406468YA (en) 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
NZ706836A (en) 2012-10-15 2019-02-22 Epizyme Inc Methods of treating cancer
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
EP2931707A4 (en) 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CN105102446B (zh) 2013-02-11 2018-01-23 星座制药公司 甲基修饰酶的调节剂、其组合物及用途
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
JP2016533364A (ja) 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
KR102302830B1 (ko) 2014-03-17 2021-09-15 다이이찌 산쿄 가부시키가이샤 1,3-벤조디옥솔 유도체
CN106999498B (zh) 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
CR20160574A (es) 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida
MX2016017097A (es) 2014-06-19 2017-05-01 Memorial Sloan Kettering Cancer Center Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2016066697A1 (en) 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
US20180037568A1 (en) 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016140501A1 (en) 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
UY36758A (es) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2

Also Published As

Publication number Publication date
ECSP18014798A (es) 2018-04-30
MD3341379T2 (ro) 2020-01-31
EP3341379A1 (en) 2018-07-04
BR112018003108A2 (pt) 2018-09-25
SI3341379T1 (sl) 2019-11-29
WO2017035060A1 (en) 2017-03-02
PE20181025A1 (es) 2018-06-27
US20170066780A1 (en) 2017-03-09
ES2756603T3 (es) 2020-04-27
MX2018002484A (es) 2018-06-15
US9718838B2 (en) 2017-08-01
LT3341379T (lt) 2019-12-10
HRP20192101T1 (hr) 2020-02-21
AU2016313541A1 (en) 2018-02-15
TW201718598A (zh) 2017-06-01
JP6704040B2 (ja) 2020-06-03
HUE047630T2 (hu) 2021-12-28
EP3341379B1 (en) 2019-10-09
PH12018500423A1 (en) 2018-08-29
CY1122364T1 (el) 2021-01-27
JP2018530527A (ja) 2018-10-18
KR20180030704A (ko) 2018-03-23
CR20180104A (es) 2018-04-24
CA2994428A1 (en) 2017-03-02
CN107922434B (zh) 2020-06-19
IL257061A (en) 2018-03-29
RS59615B1 (sr) 2020-01-31
PL3341379T3 (pl) 2020-05-18
ME03650B (me) 2020-07-20
PT3341379T (pt) 2019-12-16
CN107922434A (zh) 2018-04-17
CO2018002033A2 (es) 2018-05-21
DOP2018000058A (es) 2018-03-30
TN2018000058A1 (en) 2019-07-08

Similar Documents

Publication Publication Date Title
DK3442972T3 (da) Bromdomænehæmmere
CL2016002502A1 (es) Inhibidores de biaril cinasa
MA53944A (fr) Inhibiteurs de la glycosidase
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
DK3160952T3 (da) Histone demethylase inhibitors
DK3341379T3 (da) EZH2-hæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3481826T3 (da) Tyrosinkinaseinhibitorer